Endo International Plc (ENDP):企業の財務・戦略的SWOT分析

◆英語タイトル:Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15905
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Endo International Plc (ENDP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies. It sells generic products principally in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women’s health among others. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrinology and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors, to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc Key Recent Developments

Mar 23,2019 Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study
Mar 04,2019 Right on Brands (RTON) Exclusive Distribution Deal With South Florida Budweiser Distributor For ENDO Brands Products Kicks off sales week
Mar 01,2019 Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting
Feb 28,2019 Endo reports fourth-quarter and full year 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Endo International Plc – Key Facts
Endo International Plc – Key Employees
Endo International Plc – Key Employee Biographies
Endo International Plc – Major Products and Services
Endo International Plc – History
Endo International Plc – Company Statement
Endo International Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Endo International Plc – Business Description
Business Segment: International Pharmaceuticals
Overview
Performance
Business Segment: U.S. Branded – Specialty & Established Pharmaceuticals
Overview
Performance
Business Segment: U.S. Branded – Sterile Injectables
Overview
Performance
Business Segment: U.S. Generic Pharmaceuticals
Overview
Performance
R&D Overview
Endo International Plc – Corporate Strategy
Endo International Plc – SWOT Analysis
SWOT Analysis – Overview
Endo International Plc – Strengths
Endo International Plc – Weaknesses
Endo International Plc – Opportunities
Endo International Plc – Threats
Endo International Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Endo International Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 23, 2019: Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study
Mar 04, 2019: Right on Brands (RTON) Exclusive Distribution Deal With South Florida Budweiser Distributor For ENDO Brands Products Kicks off sales week
Mar 01, 2019: Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting
Feb 28, 2019: Endo reports fourth-quarter and full year 2018 financial results
Jan 15, 2019: BGS-649 Phase 2b data to be Presented at ENDO 2019
Nov 28, 2018: Amsel Medical Corporation Announces Clearance of a 510(k) Pre-Marketing Notification by the US Food and Drug Administration for the Amsel Endo Occluder Device
Nov 09, 2018: Endo Pharmaceuticals Issues Voluntary Recall of Robaxin Tablets Bottle Packs due to Labeling Error
Nov 08, 2018: Endo reports third-quarter 2018 financial results
Oct 11, 2018: Endo presents data on the perception and measurement of cellulite severity at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
Sep 28, 2018: Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Endo International Plc, Key Facts
Endo International Plc, Key Employees
Endo International Plc, Key Employee Biographies
Endo International Plc, Major Products and Services
Endo International Plc, History
Endo International Plc, Other Locations
Endo International Plc, Subsidiaries
Endo International Plc, Key Competitors
Endo International Plc, Ratios based on current share price
Endo International Plc, Annual Ratios
Endo International Plc, Annual Ratios (Cont...1)
Endo International Plc, Annual Ratios (Cont...2)
Endo International Plc, Interim Ratios
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Endo International Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Endo International Plc, Performance Chart (2014 - 2018)
Endo International Plc, Ratio Charts
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Endo International Plc (ENDP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • American Caresource Holdings Inc (GNOW):企業財務及び戦略的SWOT分析
    Summary American Caresource Holdings Inc (ACS) is a healthcare service provider that offers urgent and primary care services. The center’s services include urgent care, veterans care, primary care, and occupational health services. Its urgent care services offer treatment for chest pain, abdominal p …
  • Central Foods Limited:企業概要およびSWOT分析
    Summary Canadean's "Central Foods Limited : Foodservice - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company hist …
  • Aepona, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Aepona, Ltd. Mergers and Acquis …
  • Tasly Pharmaceutical Group Co., Ltd. (600535):企業のM&A・提携動向(医療機器分野)
    Summary Tasly Pharmaceutical Group Co., Ltd. (Tasly), formerly Tianjin Tasly Pharmaceutical Co., Ltd., is a pharmaceutical company. It manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM) and functional food. The company's produ …
  • VTB Bank:戦略・SWOT・企業財務分析
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • HAI Argochem Joint Stock Company (HAI):企業の財務及び戦略的SWOT分析
    Summary HAI Argochem Joint Stock Company (HAI JSC) is a chemical company that offers pesticides. The company manufactures and trades agricultural chemical products. Its products include insecticides, fungicides, herbicides, plant growth regulators and fertilizers. HAI JSC also sells corn seeds, plas …
  • Merrimack Pharmaceuticals Inc (MACK):医療機器:M&Aディール及び事業提携情報
    Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (mark …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Kwang Dong Pharmaceutical Co Ltd (009290):企業のM&A・提携動向(医療分野)
    Summary Kwang Dong Pharmaceutical Co Ltd (Kwang Dong) is a drug manufacturing company that develops, manufactures and supplies of pharmaceutical products, health drinks and supplements. The company’s pharmaceutical product includes Xelocan, Rosuridine, Atrazine, BEAUTAMIN injection, RIDBON tablets, …
  • Kencana Petroleum Berhad:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Kencana Petroleum Berhad Merger …
  • Egdon Resources Plc (EDR):企業のM&A・提携動向(石油・ガス分野)
    Summary Egdon Resources Plc (Egdon) is an oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets. Its assets include PEDL005, PEDL068, PEDL070, PEDL126, PEDL143, PEDL181, and PEDL182 Broughton. Egdon’s PEDL005 asset is …
  • Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Inovio Pharmaceuticals, Inc. (f …
  • InMed Pharmaceuticals Inc. (CBIS):企業の財務及び戦略的SWOT分析
    Summary InMed Pharmaceuticals Inc. (InMed) is a pharmaceutical company which focuses on developing therapeutics. It develops, produces and markets plant cannabinoid based pharmaceutical products to related healthcare markets. The company’s pipeline products are developed for the therapeutic areas of …
  • K Way Information Corporation (5201):企業財務及び戦略的SWOT分析
    Summary K Way Information Corporation (K Way) is an information technology company that provides software solutions. The company designs and develops application software products and solutions to banking industry. Its solutions include latency trading solutions, tailor-made settlement solution, e-t …
  • Tubacero, S. de RL de CV:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Tubacero, S. de RL de CV" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly …
  • EnBW Energie Baden-Wuerttenberg AG:企業の戦略・SWOT・財務分析
    SummaryEnBW Energie Baden-Wuerttenberg AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the c …
  • Pierre & Vacances SA (VAC):企業の財務・戦略的SWOT分析
    Pierre & Vacances SA (VAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Monopar Therapeutics LLC:企業のM&A・提携動向(医療分野)
    Summary Monopar Therapeutics LLC (Monopar) is a biopharmaceutical company that focused on the development of orphan oncology compounds. The company’s lead compound, huATN-658, an anti-urokinase plasminogen activator receptor (uPAR) monoclonal antibody intended for the potential treatment of various …
  • Galenika-Fitofarmacija ad Zemun (FITO):企業財務及び戦略的SWOT分析
    Summary Galenika-Fitofarmacija ad Zemun (Galenika-Fitofarmacija) is a chemical company that develops agricultural products and agricultural chemicals. The company also produces pesticides such as fungicides, herbicides, insecticides and rodenticides. It produces and packages formulations such as emu …
  • Euronav NV (EURN):石油・ガス:M&Aディール及び事業提携情報
    Summary Euronav NV (Euronav) is a transportation and logistics company that offers shipping services. The company provides sea-borne transportation, tanker shipping, proactive management, fleet composition and ship management services, among others. It offers ship management services which includes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆